Combinations of lsd1 inhibitors for use in the treatment of solid tumors
AssigneeHoffmann-La Roche Inc.
InventorsMark D. DEMARIO, Tamara MAES, William E. PIERCEALL, Fiona MACK, Serena LUNARDI
Life of this patent
Estimating the term…
Abstract
The instant invention relates to therapeutic combinations of LSD1 inhibitors and one or more other active pharmaceutical ingredient(s) or pharmaceutically acceptable salts thereof. The combinations are particularly useful for treating neoplastic diseases, such as cancer, particularly small cell lung cancer (SCLC).
Claims37
A therapeutic combination comprising an LSD1 inhibitor or a pharmaceutically acceptable salt thereof, and one or more active pharmaceutical ingredients selected from BCL2 inhibitors, BET inhibitors, EZH2 inhibitors, DOT1L inhibitors, Chk inhibitors, DNA alkylating agents, HDAC inhibitors, topoisomerase inhibitors, anti-mitotic agents, Aurora kinase inhibitors and pharmaceutically acceptable salts thereof.
A therapeutic combination comprising an LSD1 inhibitor or a pharmaceutically acceptable salt thereof, and one or more active pharmaceutical ingredients selected from the list of ABT-199, ABT-263, ABT-737, ABT-888, ACY-1215, Belinostat, Bendamustine, BGJ398, BMS-906024, Carboplatin, CGK 733, Cisplatin, CPI-169, CPI-203, Docetaxel, Doxorubicin, EPZ-004777, EPZ005687, EPZ-5676, EPZ-6438, Erlotinib, Etoposide, FLI 06, Fluorouracil, GDC-0449, Gemcitabine, GSK126, GSK1324726A, GSK343, GSK-J1, GSK1210151A, Irinotecan, (+)-JQ1, Lapatinib, LDE225, LY2603618, LY-3039478, Menadione, Methotrexate, MK-0752, MLN8237, MS 436, Nutlin-3A, Obatoclax, OTX015, Paclitaxel, Panobinostat, Pemetrexed, PF-04217903, PF-3084014, SAHA, SGC 0946, SNDX-275, Taladegib, Temozolomide, Topotecan, TW-37, Vincristine and pharmaceutically acceptable salts thereof.
28-30. (canceled)
34-35. (canceled)
(canceled)
Dependencies are inferred from the claim text.